kabutan

Oncolys BioPharma Inc. <4588> rises as OBP-301 receives FDA fast track designation in U.S.

Fri Apr 24, 2026 10:27 am JST Catalyst

Oncolys BioPharma Inc. <4588> traded firmly higher. After the close of trading on the 23rd, the company announced that it has received fast track designation from the U.S. Food and Drug Administration (FDA) for a treatment targeting unresectable gastroesophageal cancer using the oncolytic virus OBP-301 in combination with radiation therapy. The fast track designation is a program designed to expedite the review of drugs for serious conditions or diseases with unmet medical needs. OBP-301 received orphan drug designation in the United States in 2020.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles